

erlotinib (TARCEVA)

Diagnoses Considered for Coverage:

- Chordoma
- Non-small cell lung cancer (NSCLC) - locally advanced or metastatic
- Pancreatic cancer - unresectable, locally advanced, or metastatic
- Kidney cancer (renal cell carcinoma)

Coverage Criteria:

For non-small cell lung cancer:

- Provider attestation for the presence of EGFR gene mutation, **and**
- One of the following:
 - Being used as a single agent, or
 - Being used in combination with ramucirumab or bevacizumab, **and**
- Dose does not exceed 150 mg per day

For pancreatic cancer:

- Being used in combination with gemcitabine (Gemzar), **and**
- Dose does not exceed 100 mg per day

For chordoma:

- Being used for recurrent conventional or chondroid chordoma, **and**
- Being used as a single agent, **and**

For kidney cancer:

- Being used for relapsed or stage IV (metastatic) disease, **and**
- Histology is non-clear cell, **and**
- Dose does not exceed 150 mg per day, **and**
- Either of the following:
 - Being used as single agent, **or**
 - Being used in combination with bevacizumab for papillary RCC (including hereditary leiomyomatosis and renal cell carcinoma (HLRCC)-associated RCC)

Coverage Duration: one year

Effective Date: 8/30/2023